OBJECTIVE Antipsychotic drugs are generally registered for treating schizophrenia, psychosis, mania and conditions of severe (locomotory) agitation. In common practice, however, they are prescribed in a wide range of different psychiatric disorders. We aimed to map out the indication for use of antipsychotic drugs in the community pharmacy. METHOD We conducted a retrospective, exploratory study to examine off-label use of antipsychotics and possibly sex differences. We defined antipsychotic use as quasi-label, when used in non-registered disorders, which have psychosis as an inherent comorbidity. When antipsychotics were prescribed in disorders, which are generally not known with psychosis, we defined this as off-label use. In this study, we combined pharmacy records with data from general practitioners in order to evaluate the range of diagnoses for which antipsychotic drugs are used. We focused on sex differences in type of disorder and in prescribed dosages of antipsychotic drugs. RESULTS Among 97 male and 95 female antipsychotic users, we could classify women significantly more often as on-label antipsychotic drug users, compared to men. Most often, this occurred with typical antipsychotic drug treatment. While female patients used equal dosages for on-label and quasi-/off-label indications, we found male patients using significant lower dosages in quasi-/off-label indications, compared to on-label indications. CONCLUSION We suggest elaborate future research to the characteristics of quasi-and off-label antipsychotic drug use, in order to define effective and save use of antipsychotic drugs among off-label indications.
Introduction
Since the mid fifties of the 20 th century, antipsychotics are substances of first choice in treating a range of disorders with psychotic symptomatology [1] [2] [3] . Classic antipsychotics are mainly registered for treatment of psychosis, mania and conditions of severe locomotory agitation [4;5] . Beside these registered indications, they are commonly applied for a variety of different diagnoses including Gilles de la Tourette, Huntington disease, anti-emesis and hiccup [4;5;6] . Modern, atypical antipsychotics are only registered for use in schizophrenia [4;5;7] . However, the atypical antipsychotic drugs are often prescribed for conditions other than schizophrenia, including dementia and severe (geriatric) agitation [8;9] . The extent of this so-called off-label use is not known exactly, but earlier research revealed numbers up to 70% [7;10-13] . Some of these extended indications are described in case reports and open trials, suggesting a ground of evidence for using the antipsychotic drug for off-label indications.
However, most often these suggestions are not based on well-designed studies and the risk/benefit ratio in off-label use is not established. This ratio may have different consequences for use in male and female patients, since there may be important gender differences in the pharmacokinetics of antipsychotic drugs [14] . For on-label indications, research has mainly been performed on male subjects, however, several studies have established sex differences in effectivity and safety of antipsychotic drug use [15;16] . To our knowledge, no data are available concerning sex differences in off-label use of antipsychotic drugs.
The aim of this explorative study was to analyse sex-specific characteristics of off-label antipsychotic drug use in a community setting, in order to describe variance in indications and dosages.
Methods
We conducted a retrospective, explorative study. Data were collected from a local health care centre in the northern Netherlands. The centre consisted of a family doctor's practice with four general practitioners and a community pharmacy with two pharmacists. They constituted a peer review group in association with two external general practitioners. Pharmacy data were used to select patients who were prescribed any antipsychotic medication (classified according to the Anatomical, Therapeutical and Chemical classification (ATC [17] ) between January 1 1996 and December 31 1998. Subjects using lithium as monotherapy were excluded. All patients of general practitioners who were members of the peer review group were selected. Of these subjects, prescription records of antipsychotics, both locally and out-clinic prescribed between January 1 1996 and December 31 1998, were collected from the pharmacy database. Per selected patient a questionnaire was sent to the accompanying general practitioner, inquiring for data about diagnosis, diagnosing physician, initiator and prescriber of the antipsychotic medication. All questionnaires were processed to datafiles and connected to the prescription records. All data were anonymised.
Consumption of antipsychotic drugs was divided in three categories: onlabel, quasi-label and off-label use. Psychosis, mania, schizophrenia and severe locomotory agitation were entitled as on-label use (registered indications). Quasilabel use was defined as using antipsychotic drugs for non-registered indications, which in general have a psychotic component or a condition of severe agitation (an on-label component) as a co-syndrome. Off-label use was entitled to psychiatric indications that in general have no psychotic of severe agitation component. See For each drug the WHO has defined a standard doses for the most important indication, the Defined Daily Dose (DDD). In order to compare antipsychotic doses Prescribed Daily Dose (PDD) were calculated by counting the amount of DDDs a patient used in the study period, divided by the total amount of days a patient used the medication in the study period. Depot antipsychotics were excluded because of difficulties calculating reliable PDD.
Data analysis was performed with SPSS 10.0 for Windows. Comparisons between groups were made by using Student t-tests and χ 2 -tests.
Results
Our study population consisted of 97 male and 95 female antipsychotic medication users. In both sexes, at least 65 % of the people were between the age of 20 to 49 years. Table 1 shows various indications for antipsychotic drug use. Women (65.3 %), compared to men (48.6 %), used significantly more often antipsychotic drugs for on-label indications (χ 2 , p = 0.02). Male patients (33.2 %) used significantly more often (χ 2 , p = 0.04) antipsychotic drugs for the quasi-/ or off-label indications, compared to female patients (20.0 %).
Both male (83/97) and female (84/95) patients used significantly more (p < 0.005) typical antipsychotic drugs in the study period, compared to the use of atypical antipsychotics (32/97 versus 25/95, respectively, table 2a and 2b). Women more often were prescribed typical antipsychotics for on-label indications, compared to males (p = 0.04), in significantly lower dosages (p = 0.007). There was a clear sex difference between the average daily dose used in on-label and quasi-/off-label indications. Male patients used both typical antipsychotics (PDD on-label 0.86 versus PDD quasi-/off-label 0.45) and atypical antipsychotics (PDD on-label 0.82 versus PDD quasi-/off-label 0.42) in significantly lower dosages with quasi-/off-label indications, compared to on-label use (p = 0.009 and p = 0.03, respectively). We could not demonstrate this difference between on-label and quasi-/off-label use in women.
In both male and female patients, diagnosing the disease and starting medication was most often initiated by hospital psychiatrists (63.9% versus 69.4%, not shown in table 3). Among these, prescription of antipsychotic drugs for onlabel indications occurred in 59.6 % of male patients, compared to 68.2% of female patients (χ 2 , p = 0.32). In case general practitioners made diagnosis and initiated antipsychotic drug therapy, 76.9 % of the women used medication for on-label indications, compared to 40.0 % of male patients (Fisher exact, p = 0.06). 
Discussion
This explorative study shows that antipsychotic drugs are prescribed for a broad range of indications, but most often for on-label or quasi-label indications. Women used antipsychotic drugs significantly more often for on-label indications compared to men. Male patients used significant lower dosages of both typical and atypical antipsychotic drugs in quasi-/off-label indications, compared to antipsychotic use in on-label indications. We could not demonstrate this difference in women. In the majority of the patients, hospital psychiatrists initiated and maintained antipsychotic drug therapy, most often for on-label indications.
In this study, we used the general practitioner as a source for obtaining the diagnosis for antipsychotic use. The accessibility of data regarding reasons for prescribing is facilitated in a health care centre environment. Reliability of these data is dependent on communication between psychiatrist and general practitioner. Diagnosis and prescription of more than ten percent of the antipsychotic users was not known by the GP of the patient, suggesting that communication between professionals in healthcare can be improved. Documentation about patients is mainly exchanged by mail between secondary and primary care. Lack or loss of documentation, recent admission to psychiatric services or change of diagnosis may be reasons for GP's not knowing the psychiatric illness of their patient. Nevertheless, since interprofessional communication is common practice in the Netherlands, making inquiries after diagnosis is probably more objective from datafiles of general practitioners compared to surveying patients, since fear of stigma or missing confidence in the interviewer may influence the results (Weiss et al. [12] ). 
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The classic antipsychotic drugs are primarily registered for main indications like psychosis, mania, schizophrenia and severe locomotory agitation. For these on-label indications evidence-based knowledge on effective dosages and occurrence of adverse effects is available. Psychosis may also be a complication from a range of other psychiatric disorders, frequently giving cause for use of antipsychotics. A crude investigation of Medline (1995 ( -October 2001 showed that of all the quasi-label and off-label indications we found in this study, the option of treating these with antipsychotic drugs was described several times in case reports, open-label studies or commentaries. However, there is a general shortage of double-blind, randomised controlled clinical trials of typical antipsychotic drugs for off-label indications, examining mean effective dosages, safety profiles and sex differences. For atypical antipsychotics, literature about offlabel use is mainly restricted to conditions of severe agitation (like in dementia or Gilles de la Tourette disease) and to affective disorders (mania) [7] .
In accordance with earlier studies in on-label indications, we found that men needed equivalents or higher dosages of antipsychotic drugs, compared to women [14-16;18] . If women used antipsychotic drugs for quasi-/off-label indications, dosages did not differ from on-label indications. However, in contrast with females, male patients used significant lower dosages in quasi-/off-label indications, compared with on-label indications. Weiss et al. [12] found occurence of fewer side effects in off-label indications and suggested this could be due to dose differences between on-label and off-label use. Although Weiss et al. [12] did not analyse sex differences, we think our research may confirm their suggestion, since the average PDD of antipsychotics in male and female patients together will indeed be lower in quasi-/ off-label use compared to on-label use. Therefore, we suggest further investigation to dose differences during quasi-and off-label use of antipsychotic drugs.
In the Netherlands, patients first attending their general practitioner with psychiatric disorders are generally referred to a hospital psychiatrist. He or she is the main initiator of an antipsychotic medication regimen, as our research confirms. Still up to 15 % of the patients are adjusted to antipsychotics by general practitioners. Although numbers are small, we found significant difference in GPprescribing behaviour towards male and female patients. General practitioners are in general less experienced in prescribing antipsychotic treatment. This can explain their caution in prescribing antipsychotic drugs for quasi-/off-label indications in women. Furthermore, they, but also psychiatrists, may expect risks involving reproduction or frequent occurrence of side effects in women, since earlier research suggests possible differences in response and safety of antipsychotics among males and females [14] [15] [16] . However, there is hardly any evidence based effect-or safety profile for either men or women in off-label use of antipsychotics.
Thus, there is an urgent need for future research to quasi-and off-label use of antipsychotic drugs, in order to establish effective treatment of these indications and to prevent the occurrence of unexpected side effects.
